Wed, Jun 24, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
Aynaz Asgharvand Hajeb1 
, Reza Safaralizadeh *2 , Mohammadali Hossienpourfeizi3 , Elmira Aboutalebi Vand Beilankouhi3
, Reza Safaralizadeh *2 , Mohammadali Hossienpourfeizi3 , Elmira Aboutalebi Vand Beilankouhi3
1- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
2- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. ,safaralizadeh@tabrizu.ac.ir
3- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
2- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. ,
3- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Abstract: (8 Views)
Background: Colorectal cancer (CRC) is a common and multifactorial malignancy influenced by both genetic and environmental factors. Long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor initiation and progression. Previous studies have linked HNF1A-AS1 and MCM3AP-AS1 expression to clinicopathological features in several cancers. This case–control study aimed to evaluate the expression levels of these lncRNAs in CRC tissues before and after chemotherapy with capecitabine and celecoxib, compared with non-cancerous control tissues.
Methods: Tissue samples were collected from 98 CRC patients before and after chemotherapy and from 71 non-cancerous controls obtained during colonoscopy or surgery. Total RNA was extracted, reverse transcribed into cDNA, and gene expression levels were quantified using real-time quantitative PCR.
Results: Both HNF1A-AS1 and MCM3AP-AS1 were significantly upregulated in CRC tissues before treatment compared with controls (p = 0.0051 and p = 0.0393, respectively). However, no significant differences in expression were observed between pre- and post-treatment samples (p > 0.05). ROC curve analysis revealed weak diagnostic performance for each lncRNA individually, whereas their combined analysis showed modest diagnostic value (AUC = 0.66). Chemotherapy was associated with an improvement in mean patient survival of approximately 16 months.
Conclusion: Chemotherapy with capecitabine and celecoxib did not significantly alter the expression of HNF1A-AS1 or MCM3AP-AS1 in CRC patients, despite improved survival outcomes. The combined assessment of these lncRNAs may have limited diagnostic utility, but they do not appear to be suitable biomarkers for monitoring chemotherapy response.
Methods: Tissue samples were collected from 98 CRC patients before and after chemotherapy and from 71 non-cancerous controls obtained during colonoscopy or surgery. Total RNA was extracted, reverse transcribed into cDNA, and gene expression levels were quantified using real-time quantitative PCR.
Results: Both HNF1A-AS1 and MCM3AP-AS1 were significantly upregulated in CRC tissues before treatment compared with controls (p = 0.0051 and p = 0.0393, respectively). However, no significant differences in expression were observed between pre- and post-treatment samples (p > 0.05). ROC curve analysis revealed weak diagnostic performance for each lncRNA individually, whereas their combined analysis showed modest diagnostic value (AUC = 0.66). Chemotherapy was associated with an improvement in mean patient survival of approximately 16 months.
Conclusion: Chemotherapy with capecitabine and celecoxib did not significantly alter the expression of HNF1A-AS1 or MCM3AP-AS1 in CRC patients, despite improved survival outcomes. The combined assessment of these lncRNAs may have limited diagnostic utility, but they do not appear to be suitable biomarkers for monitoring chemotherapy response.
Type of Study: Original Research Article |
Subject:
Clinical Medicine
Received: 2025/08/14 | Accepted: 2026/06/22
Received: 2025/08/14 | Accepted: 2026/06/22
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Farname Inc. is licensed under CC BY-NC 4.0
